JP4664592B2 - 活性型第十因子阻害剤としてのインドール−２−カルボキシアミド - Google Patents
活性型第十因子阻害剤としてのインドール−２−カルボキシアミド Download PDFInfo
- Publication number
- JP4664592B2 JP4664592B2 JP2003545651A JP2003545651A JP4664592B2 JP 4664592 B2 JP4664592 B2 JP 4664592B2 JP 2003545651 A JP2003545651 A JP 2003545651A JP 2003545651 A JP2003545651 A JP 2003545651A JP 4664592 B2 JP4664592 B2 JP 4664592B2
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- indole
- ylmethyl
- thiophen
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Cc1c(*)c(*)c(c(*)c(C(*)=O)[n]2*)c2c1* Chemical compound Cc1c(*)c(*)c(c(*)c(C(*)=O)[n]2*)c2c1* 0.000 description 2
- CKXZPVPIDOJLLM-UHFFFAOYSA-N CC(C)(C)OC(NC1CCNCC1)=O Chemical compound CC(C)(C)OC(NC1CCNCC1)=O CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- YNGBTQWWOMFMNU-UHFFFAOYSA-N CC(C)N(CC1)CCC1NC(c([n](Cc1n[o]c(-c([s]2)ccc2Cl)c1)c1ccccc11)c1C#N)=O Chemical compound CC(C)N(CC1)CCC1NC(c([n](Cc1n[o]c(-c([s]2)ccc2Cl)c1)c1ccccc11)c1C#N)=O YNGBTQWWOMFMNU-UHFFFAOYSA-N 0.000 description 1
- ALODELTWBLGZGB-UHFFFAOYSA-N CC(C)N(CC1)CCC1NC(c1cc(cc(cc2)C(OCOC(C(C)(C)C)=O)=O)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O Chemical compound CC(C)N(CC1)CCC1NC(c1cc(cc(cc2)C(OCOC(C(C)(C)C)=O)=O)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O ALODELTWBLGZGB-UHFFFAOYSA-N 0.000 description 1
- UUWXQABINFEYRX-UHFFFAOYSA-N CC(C)N(CC1)CCC1NC(c1cc2c(C)ccc(C)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O Chemical compound CC(C)N(CC1)CCC1NC(c1cc2c(C)ccc(C)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O UUWXQABINFEYRX-UHFFFAOYSA-N 0.000 description 1
- NPNNJZJVTXOACX-UHFFFAOYSA-N CC(C)N(CC1)CCC1NC(c1cc2cc(C#N)ccc2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O Chemical compound CC(C)N(CC1)CCC1NC(c1cc2cc(C#N)ccc2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O NPNNJZJVTXOACX-UHFFFAOYSA-N 0.000 description 1
- OEACEEHJARIXJW-UHFFFAOYSA-N CC(C)N(CC1)CCC1NC(c1cc2cc(C(O)=O)ccc2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O Chemical compound CC(C)N(CC1)CCC1NC(c1cc2cc(C(O)=O)ccc2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O OEACEEHJARIXJW-UHFFFAOYSA-N 0.000 description 1
- PJTYIXSRDGSRKB-UHFFFAOYSA-N CC(C)N(CC1)CCC1NC(c1cc2ccccc2[n]1-c(cc1)ccc1Cl)=O Chemical compound CC(C)N(CC1)CCC1NC(c1cc2ccccc2[n]1-c(cc1)ccc1Cl)=O PJTYIXSRDGSRKB-UHFFFAOYSA-N 0.000 description 1
- AYWFFTBSKJPXKS-UHFFFAOYSA-N CC(C)N(CC1)CCC1NC(c1cc2ccccc2[n]1-c1cc(Cl)ccc1)=O Chemical compound CC(C)N(CC1)CCC1NC(c1cc2ccccc2[n]1-c1cc(Cl)ccc1)=O AYWFFTBSKJPXKS-UHFFFAOYSA-N 0.000 description 1
- SJVNXORPJTWERP-UHFFFAOYSA-N CC(C)N(CC1)CCC1NC(c1cc2ccccc2[n]1Cc(cc1)cc2c1c(N)ncn2)=O Chemical compound CC(C)N(CC1)CCC1NC(c1cc2ccccc2[n]1Cc(cc1)cc2c1c(N)ncn2)=O SJVNXORPJTWERP-UHFFFAOYSA-N 0.000 description 1
- LGFMFSIKXFRKMB-UHFFFAOYSA-N CC(C)N(CC1)CCC1NC(c1cc2ccccc2[n]1Cc1cccc(Cl)c1)=O Chemical compound CC(C)N(CC1)CCC1NC(c1cc2ccccc2[n]1Cc1cccc(Cl)c1)=O LGFMFSIKXFRKMB-UHFFFAOYSA-N 0.000 description 1
- UQSDRADXDFZXQQ-UHFFFAOYSA-N CC(C)NC(CC1)CCN1C(c1cc2ccccc2[n]1Cc(cc1)ccc1OC(F)(F)F)=O Chemical compound CC(C)NC(CC1)CCN1C(c1cc2ccccc2[n]1Cc(cc1)ccc1OC(F)(F)F)=O UQSDRADXDFZXQQ-UHFFFAOYSA-N 0.000 description 1
- RKRLQDJTVWZXMM-UHFFFAOYSA-N CC(N1)=NOC1=O Chemical compound CC(N1)=NOC1=O RKRLQDJTVWZXMM-UHFFFAOYSA-N 0.000 description 1
- QYIOFABFKUOIBV-UHFFFAOYSA-N CC(O1)=C(C)OC1=O Chemical compound CC(O1)=C(C)OC1=O QYIOFABFKUOIBV-UHFFFAOYSA-N 0.000 description 1
- NNXROHRFMWHXNH-UHFFFAOYSA-N CC(O1)=NNC1=O Chemical compound CC(O1)=NNC1=O NNXROHRFMWHXNH-UHFFFAOYSA-N 0.000 description 1
- JCISJJATYPEPNN-UHFFFAOYSA-N CCOC(CN(C(CC1)CCN1C(C)C)C(c1cc2c(C(F)(F)F)cccc2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O)=O Chemical compound CCOC(CN(C(CC1)CCN1C(C)C)C(c1cc2c(C(F)(F)F)cccc2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O)=O JCISJJATYPEPNN-UHFFFAOYSA-N 0.000 description 1
- LFYIIEJEMXSFCY-UHFFFAOYSA-N COC(N(CC1)CCC1NC(c1cc(cccc2)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O)=O Chemical compound COC(N(CC1)CCC1NC(c1cc(cccc2)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O)=O LFYIIEJEMXSFCY-UHFFFAOYSA-N 0.000 description 1
- XADINPIVVUHTDF-UHFFFAOYSA-P C[S+](N(CC1)CCC1NC(c1cc2ccccc2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O)(O)=O Chemical compound C[S+](N(CC1)CCC1NC(c1cc2ccccc2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)=O)(O)=O XADINPIVVUHTDF-UHFFFAOYSA-P 0.000 description 1
- OWXTYWIXNMQSQE-UHFFFAOYSA-N O=C(c1cc(cccc2)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)N(CC1)CCC1N1CCCCC1 Chemical compound O=C(c1cc(cccc2)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)N(CC1)CCC1N1CCCCC1 OWXTYWIXNMQSQE-UHFFFAOYSA-N 0.000 description 1
- UPZFSDPZCQPKHL-UHFFFAOYSA-N O=C(c1cc(cccc2)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)N(CC1)CCC1Oc1ccncc1 Chemical compound O=C(c1cc(cccc2)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)N(CC1)CCC1Oc1ccncc1 UPZFSDPZCQPKHL-UHFFFAOYSA-N 0.000 description 1
- CNSWKIVXGHMTPX-UHFFFAOYSA-N O=C(c1cc(cccc2)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)Nc1nc(-c2cccnc2)c[s]1 Chemical compound O=C(c1cc(cccc2)c2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)Nc1nc(-c2cccnc2)c[s]1 CNSWKIVXGHMTPX-UHFFFAOYSA-N 0.000 description 1
- HOKZZMAWZICCKZ-UHFFFAOYSA-N O=C(c1cc2ccccc2[n]1Cc(cc1)ccc1Cl)NCC(CC1)CCN1c1ccncc1 Chemical compound O=C(c1cc2ccccc2[n]1Cc(cc1)ccc1Cl)NCC(CC1)CCN1c1ccncc1 HOKZZMAWZICCKZ-UHFFFAOYSA-N 0.000 description 1
- VTVNGWNXLGINQY-UHFFFAOYSA-N O=C(c1cc2ccccc2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)NC1CCNCC1 Chemical compound O=C(c1cc2ccccc2[n]1Cc1n[o]c(-c([s]2)ccc2Cl)c1)NC1CCNCC1 VTVNGWNXLGINQY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01127809A EP1314733A1 (en) | 2001-11-22 | 2001-11-22 | Indole-2-carboxamides as factor Xa inhibitors |
| PCT/EP2002/012500 WO2003044014A1 (en) | 2001-11-22 | 2002-11-08 | Indole-2-carboxamides as factor xa inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005514365A JP2005514365A (ja) | 2005-05-19 |
| JP2005514365A5 JP2005514365A5 (https=) | 2006-01-05 |
| JP4664592B2 true JP4664592B2 (ja) | 2011-04-06 |
Family
ID=8179313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003545651A Expired - Fee Related JP4664592B2 (ja) | 2001-11-22 | 2002-11-08 | 活性型第十因子阻害剤としてのインドール−２−カルボキシアミド |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US6906084B2 (https=) |
| EP (2) | EP1314733A1 (https=) |
| JP (1) | JP4664592B2 (https=) |
| KR (2) | KR101033798B1 (https=) |
| CN (1) | CN1283638C (https=) |
| AR (1) | AR037656A1 (https=) |
| AU (1) | AU2002351918B2 (https=) |
| BR (1) | BR0214396A (https=) |
| CA (1) | CA2467374C (https=) |
| CO (1) | CO5580764A2 (https=) |
| EC (1) | ECSP045115A (https=) |
| HR (1) | HRP20040453A2 (https=) |
| HU (1) | HUP0402063A3 (https=) |
| IL (2) | IL162105A0 (https=) |
| MA (1) | MA27350A1 (https=) |
| ME (1) | MEP43008A (https=) |
| MX (1) | MXPA04004797A (https=) |
| MY (1) | MY131516A (https=) |
| NO (1) | NO327466B1 (https=) |
| NZ (1) | NZ533044A (https=) |
| OA (1) | OA12727A (https=) |
| PE (1) | PE20030593A1 (https=) |
| PL (1) | PL210986B1 (https=) |
| RS (1) | RS40404A (https=) |
| RU (1) | RU2299881C2 (https=) |
| TN (1) | TNSN04091A1 (https=) |
| TW (1) | TWI291950B (https=) |
| UA (1) | UA78731C2 (https=) |
| WO (1) | WO2003044014A1 (https=) |
| ZA (1) | ZA200402945B (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100567266C (zh) | 2001-11-14 | 2009-12-09 | 先灵公司 | 类大麻苷受体配体 |
| US7358268B2 (en) * | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
| US7429581B2 (en) * | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
| EP1606289B1 (en) | 2003-02-14 | 2009-12-02 | Glaxo Group Limited | Carboxamide derivatives |
| US7539725B2 (en) * | 2003-04-03 | 2009-05-26 | Zix Corporation | Auditor system |
| US7223780B2 (en) * | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| EP1479680A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Azaindole derivatives as Factor Xa inhibitors |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| US7317027B2 (en) * | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
| EP1479677A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
| EP1479675A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
| WO2004108671A1 (en) * | 2003-06-06 | 2004-12-16 | Suven Life Sciences Limited | Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| EP1568698A1 (en) * | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
| EP1571154A1 (en) * | 2004-03-03 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Beta-aminoacid-derivatives as factor Xa inhibitors |
| ES2315877T3 (es) | 2004-06-18 | 2009-04-01 | Biolipox Ab | Indoles utiles en el tratamiento de inflamaciones. |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) * | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2006019831A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2006019832A1 (en) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
| FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| WO2006047415A2 (en) | 2004-10-26 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Factor xa compounds |
| EP1828152B1 (en) * | 2004-12-08 | 2008-08-20 | Bristol-Myers Squibb Company | Heterocyclic compounds as inhibitors of factor viia |
| MX2007008008A (es) | 2004-12-30 | 2007-11-12 | Astex Therapeutics Ltd | Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora. |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| CN101142185A (zh) | 2005-01-19 | 2008-03-12 | 比奥里波克斯公司 | 用于炎症治疗的吲哚 |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| FR2888847B1 (fr) | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US8399442B2 (en) | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
| CA2637933C (en) * | 2006-01-24 | 2013-03-12 | Eli Lilly And Company | Indole sulfonamide modulators of progesterone receptors |
| US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
| JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| MY162157A (en) * | 2007-04-16 | 2017-05-31 | Abbott Lab | Substituted indole mcl-1 inhibitors |
| CA2691512A1 (en) * | 2007-08-10 | 2009-02-19 | H. Lundbeck A/S | Heteroaryl amide analogues |
| TW200920369A (en) | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
| CA2707669C (en) * | 2007-12-07 | 2016-07-05 | Wilfried Braje | 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases |
| SG188781A1 (en) * | 2007-12-27 | 2013-04-30 | Abbott Gmbh & Co Kg | Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
| JP5328816B2 (ja) | 2008-02-22 | 2013-10-30 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβの調節薬 |
| MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Ｐｉ3ｋ 저해물질로서의 피리미디논 |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| US8486967B2 (en) * | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| EP3660016A1 (en) | 2010-12-20 | 2020-06-03 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| FR2974576B1 (fr) * | 2011-04-29 | 2013-07-19 | Sanofi Aventis | Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique |
| PT3513793T (pt) | 2011-09-02 | 2021-05-10 | Incyte Holdings Corp | Heterociclilaminas como inibidores de pi3k |
| BR112014021498A2 (pt) * | 2012-02-29 | 2017-07-18 | Institute For Hepatitis And Virus Res | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| DK2970265T3 (en) | 2013-03-15 | 2018-10-01 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| US9840489B2 (en) * | 2013-12-20 | 2017-12-12 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Piperidine carboxamide compound, preparation method, and usage thereof |
| KR102412045B1 (ko) | 2014-05-22 | 2022-06-22 | 놀스 차이나 파마수티칼 컴퍼니., 엘티디. | 혈액응고인자 Xa 억제제로서의 히드라지드 화합물 |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| BR112017004612A2 (pt) * | 2014-09-10 | 2018-01-30 | Epizyme, Inc. | compostos, composição farmacêutica, usos de um composto, e kit |
| US10351532B2 (en) | 2014-12-29 | 2019-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
| SG10201907576SA (en) | 2015-02-27 | 2019-09-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| CN107922428B (zh) * | 2015-06-25 | 2021-02-05 | 普洛麦格公司 | 噻吩并吡咯化合物及其作为刺虾源性荧光素酶的抑制剂的用途 |
| KR101725451B1 (ko) * | 2016-05-25 | 2017-04-13 | 한국화학연구원 | N-(피페리딘-4-일)-1h-인돌-2-카복스아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| SG11201901690UA (en) * | 2016-10-18 | 2019-03-28 | Chevron Oronite Tech Bv | Marine diesel lubricant oil compositions |
| US10815247B2 (en) | 2016-12-28 | 2020-10-27 | Promega Corporation | Functionalized NANOLUC inhibitors |
| SG11201908351TA (en) * | 2017-03-10 | 2019-10-30 | Edmond J Lavoie | Indole derivatives as efflux pump inhibitors |
| US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| SG11202011680YA (en) | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| AU2021405511A1 (en) * | 2020-12-22 | 2023-06-22 | Luxembourg Institute Of Health (Lih) | Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases |
| CN116332818B (zh) * | 2021-12-22 | 2023-12-15 | 王喆明 | 四氢吡咯衍生物及其应用 |
| CN116554144B (zh) * | 2022-01-27 | 2025-12-19 | 司马健 | 一种sj系列芳基苯胺类化合物及其制备方法与医药用途 |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3317524A (en) * | 1965-02-04 | 1967-05-02 | American Home Prod | Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles |
| FR2260332A1 (en) * | 1974-02-12 | 1975-09-05 | Delalande Sa | 1-Phenyl-2-aminocarbonyl-indoles - with respiratory analeptic, antiinflammatory analgesic, vasodilator, diuretic and anti-ulcer activity |
| US4675332A (en) * | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| IE68593B1 (en) * | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| TW229140B (https=) * | 1992-06-05 | 1994-09-01 | Shell Internat Res Schappej B V | |
| FR2703995B1 (fr) | 1993-04-16 | 1995-07-21 | Sanofi Elf | 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant. |
| US5518231A (en) | 1993-04-19 | 1996-05-21 | Xerox Corporation | Self adjusting sheet gripping apparatus |
| EP1384725A3 (en) | 1994-04-26 | 2007-02-21 | Aventis Pharmaceuticals Inc. | Factor Xa inhibitors |
| DE69523182T2 (de) * | 1995-06-06 | 2002-02-07 | Pfizer | Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren |
| WO1997003965A1 (en) * | 1995-07-18 | 1997-02-06 | Kyowa Hakko Kogyo Co., Ltd. | Indole derivatives |
| JPH0987282A (ja) * | 1995-09-21 | 1997-03-31 | Kyowa Hakko Kogyo Co Ltd | チアゾール誘導体 |
| AU2898297A (en) * | 1996-05-24 | 1998-01-05 | Novartis Ag | Use of substance p antagonists for treating social phobia |
| FR2763337B1 (fr) * | 1997-05-13 | 1999-08-20 | Sanofi Sa | Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant |
| GB9716657D0 (en) * | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| DK1042287T3 (da) * | 1997-12-24 | 2005-08-15 | Aventis Pharma Gmbh | Indolderivater som inhibitorer af faktor Xa |
| TR200002182T2 (tr) | 1998-01-27 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | İkame edilmiş aksozaherosayklil faktör xa inhibitörleri |
| EP0987274A1 (en) | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
| JP4241970B2 (ja) * | 1998-10-30 | 2009-03-18 | 中外製薬株式会社 | アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体 |
| JP2001002642A (ja) * | 1999-06-21 | 2001-01-09 | Nippon Nohyaku Co Ltd | 複素環ジカルボン酸ジアミド誘導体及び除草剤並びにその使用方法 |
| CN1420882A (zh) | 1999-07-28 | 2003-05-28 | 阿温蒂斯药物公司 | 取代的氧代氮杂杂环基化合物 |
| US6486211B1 (en) * | 1999-10-22 | 2002-11-26 | Smithkline Beecham Corporation | Indole compounds |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US6436965B1 (en) * | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
| WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| DE10147672A1 (de) * | 2001-09-27 | 2003-04-10 | Bayer Ag | Substituierte 2,5-Diamidoindole und ihre Verwendung |
| CN100567266C (zh) * | 2001-11-14 | 2009-12-09 | 先灵公司 | 类大麻苷受体配体 |
| EP1479677A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
| FR2888847B1 (fr) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| FR2911604B1 (fr) * | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
-
2001
- 2001-11-22 EP EP01127809A patent/EP1314733A1/en not_active Withdrawn
-
2002
- 2002-08-11 UA UA20040604882A patent/UA78731C2/uk unknown
- 2002-11-08 KR KR1020107003845A patent/KR101033798B1/ko not_active Expired - Fee Related
- 2002-11-08 RS YUP-404/04A patent/RS40404A/sr unknown
- 2002-11-08 CN CNB028232488A patent/CN1283638C/zh not_active Expired - Fee Related
- 2002-11-08 HR HR20040453A patent/HRP20040453A2/xx not_active Application Discontinuation
- 2002-11-08 CA CA2467374A patent/CA2467374C/en not_active Expired - Fee Related
- 2002-11-08 WO PCT/EP2002/012500 patent/WO2003044014A1/en not_active Ceased
- 2002-11-08 HU HU0402063A patent/HUP0402063A3/hu unknown
- 2002-11-08 ME MEP-430/08A patent/MEP43008A/xx unknown
- 2002-11-08 OA OA1200400142A patent/OA12727A/en unknown
- 2002-11-08 KR KR1020047007838A patent/KR100954508B1/ko not_active Expired - Fee Related
- 2002-11-08 AU AU2002351918A patent/AU2002351918B2/en not_active Ceased
- 2002-11-08 RU RU2004118710/04A patent/RU2299881C2/ru not_active IP Right Cessation
- 2002-11-08 PL PL368949A patent/PL210986B1/pl unknown
- 2002-11-08 EP EP02787604.4A patent/EP1451185B1/en not_active Expired - Lifetime
- 2002-11-08 IL IL16210502A patent/IL162105A0/xx unknown
- 2002-11-08 MX MXPA04004797A patent/MXPA04004797A/es active IP Right Grant
- 2002-11-08 JP JP2003545651A patent/JP4664592B2/ja not_active Expired - Fee Related
- 2002-11-08 BR BR0214396-8A patent/BR0214396A/pt active Search and Examination
- 2002-11-08 NZ NZ533044A patent/NZ533044A/en not_active IP Right Cessation
- 2002-11-19 PE PE2002001105A patent/PE20030593A1/es not_active Application Discontinuation
- 2002-11-20 AR ARP020104452A patent/AR037656A1/es active IP Right Grant
- 2002-11-20 TW TW091133782A patent/TWI291950B/zh not_active IP Right Cessation
- 2002-11-21 US US10/301,397 patent/US6906084B2/en not_active Expired - Lifetime
- 2002-11-22 MY MYPI20024375A patent/MY131516A/en unknown
-
2004
- 2004-04-19 ZA ZA2004/02945A patent/ZA200402945B/en unknown
- 2004-04-22 MA MA27647A patent/MA27350A1/fr unknown
- 2004-05-20 EC EC2004005115A patent/ECSP045115A/es unknown
- 2004-05-20 IL IL162105A patent/IL162105A/en not_active IP Right Cessation
- 2004-05-20 CO CO04046947A patent/CO5580764A2/es active IP Right Grant
- 2004-05-21 TN TNP2004000091A patent/TNSN04091A1/en unknown
- 2004-06-21 NO NO20042592A patent/NO327466B1/no not_active IP Right Cessation
- 2004-08-26 US US10/926,909 patent/US20050043302A1/en not_active Abandoned
-
2008
- 2008-05-12 US US12/119,013 patent/US20090069565A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4664592B2 (ja) | 活性型第十因子阻害剤としてのインドール−２−カルボキシアミド | |
| JP4676960B2 (ja) | 第Ｘａ因子阻害剤としてのインドール誘導体 | |
| JP4585448B2 (ja) | 第Ｘａ因子阻害剤としてのピラゾール−誘導体 | |
| US7910606B2 (en) | Pyrazole-derivatives as factor Xa inhibitors | |
| US20080280946A1 (en) | Azaindole-Derivatives As Factor Xa Inhibitors | |
| EP1479675A1 (en) | Indazole-derivatives as factor Xa inhibitors | |
| EP1433788A1 (en) | Pyrazole-derivatives as factor Xa inhibitors | |
| EP1426364A1 (en) | Imidazole-derivatives as factor Xa inhibitors | |
| US7358268B2 (en) | Imidazole derivatives as factor Xa inhibitors | |
| JP4504820B2 (ja) | Ｘａ因子阻害剤としてのイミダゾール誘導体 | |
| JP4733642B2 (ja) | 第Ｘａ因子阻害剤としてのアザインドール−誘導体 | |
| HK1070352B (en) | Indole-2-carboxamides as factor xa inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20051025 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051025 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090929 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091006 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100422 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100430 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100726 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100824 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101118 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101214 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110107 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140114 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |